These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 30957988

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
    Zhou Z, Feng Z, Hu D, Yang P, Gur M, Bahar I, Cristofanilli M, Gradishar WJ, Xie XQ, Wan Y.
    EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
    [Abstract] [Full Text] [Related]

  • 3. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK, Mahapatra S, Kesherwani V, Kling MJ, Shukla M, Ray S, Kanchan R, Perumal N, McGuire TR, Sharp JG, Joshi SS, Coulter DW.
    BMC Cancer; 2019 Nov 06; 19(1):1056. PubMed ID: 31694585
    [Abstract] [Full Text] [Related]

  • 4. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
    Breast Cancer Res; 2012 Jul 19; 14(4):R109. PubMed ID: 22812567
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J.
    J Clin Invest; 2016 Oct 03; 126(10):3961-3980. PubMed ID: 27643437
    [Abstract] [Full Text] [Related]

  • 8. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S.
    Breast Cancer Res Treat; 2015 Jun 03; 151(2):281-94. PubMed ID: 25904215
    [Abstract] [Full Text] [Related]

  • 9. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.
    Breast Cancer Res; 2015 Jun 03; 17():19. PubMed ID: 25837326
    [Abstract] [Full Text] [Related]

  • 10. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X, Zahari MS, Renuse S, Kelkar DS, Barbhuiya MA, Rojas PL, Stearns V, Gabrielson E, Malla P, Sukumar S, Mahajan NP, Pandey A.
    Oncotarget; 2017 Jan 10; 8(2):2971-2983. PubMed ID: 27902967
    [Abstract] [Full Text] [Related]

  • 11. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G, Fan X, Hao M, Wang J, Zhou X, Sun X.
    Mol Cancer; 2016 Apr 30; 15(1):30. PubMed ID: 27130446
    [Abstract] [Full Text] [Related]

  • 12. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL.
    Int J Cancer; 2014 May 15; 134(10):2424-36. PubMed ID: 24615768
    [Abstract] [Full Text] [Related]

  • 13. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B.
    Breast Cancer Res; 2019 Jul 01; 21(1):77. PubMed ID: 31262335
    [Abstract] [Full Text] [Related]

  • 14. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M, Li AQ, Zhou SL, Lv H, Wei P, Yang WT.
    J Exp Clin Cancer Res; 2020 May 24; 39(1):92. PubMed ID: 32448269
    [Abstract] [Full Text] [Related]

  • 15. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
    Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW.
    Nat Chem Biol; 2015 Jun 24; 11(6):432-7. PubMed ID: 25915199
    [Abstract] [Full Text] [Related]

  • 16. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K, Xia W, Liao HW, Saito M, Hung MC, Yamaguchi H.
    Breast Cancer; 2018 Jan 24; 25(1):74-80. PubMed ID: 28643125
    [Abstract] [Full Text] [Related]

  • 17. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT.
    Clin Cancer Res; 2017 Aug 15; 23(16):4780-4792. PubMed ID: 28465444
    [Abstract] [Full Text] [Related]

  • 18. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.
    Breast Cancer Res; 2014 Apr 07; 16(2):R36. PubMed ID: 24708766
    [Abstract] [Full Text] [Related]

  • 19. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S.
    Int J Cancer; 2016 Aug 15; 139(4):916-27. PubMed ID: 27037627
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    He Q, Zhang Y, Li W, Chen S, Xiong J, Zhao R, Yuan K, Hu Q, Liu S, Gao G, Bedford MT, Tang DG, Xu B, Zou C, Zhang D.
    Cancer Lett; 2024 Oct 10; 602():217214. PubMed ID: 39218291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.